Genomic analysis of aggressive ductal adenocarcinoma of the prostate

Kobayashi, Hiroaki; Kosaka, Takeo; Nakamura, Kazuto; Kimura, Tokuhiro; Nishihara, Hiroshi; Oya, Mototsugu

doi:10.1002/cam4.5573

Cited by 5 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xu et al found that IDC-P was a risk factor for pathological lymph node metastasis in patients with cT2N0M0 stage who underwent RP 24 . Comprehensive genome analysis revealed a higher frequency of alterations in tumor suppressor genes (e.g., TP53, RB1) for UH cancers, which may manifest as these clinical features 25 . Furthermore, PTEN de ciency was frequently observed in patients with IDC-P, at 70-90% 26 .…”

Section: Discussionmentioning

confidence: 99%

Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy

Kurokawa,

Yamada,

Sakamoto

et al. 2024

Preprint

View full text Add to dashboard Cite

The prognostic significance of unconventional histology (UH) subtypes including intraductal carcinoma of the prostate (IDC-P), ductal adenocarcinoma, and cribriform pattern has been investigated for prostate cancer (PCa). However, little is known about magnetic resonance imaging (MRI) features and the oncological impact of tumor localization in localized PCa with UH. Clinical data of 211 patients with acinar adenocarcinoma (conventional histology [CH]) and 82 patients with UH who underwent robotic-assisted radical prostatectomy (RARP) were reviewed. Patients with UH are more likely to be older and have higher Gleason grade group, higher Prostate Imaging-Reporting and Data System (PI-RADS) v2.1 score, and larger TV than those with CH. Multivariate analysis identified the presence of UH as an independent prognostic factor for biochemical recurrence (BCR) (hazard ration (HR) = 2.41, 95% confidence interval (CI): 0.22–0.79, P = 0.0073). No significant difference in BCR was seen regarding tumor localization (transition zone [TZ] or peripheral zone [PZ]) in patients with UH (P = 0.8949), whereas PZ cancer showed shorter BCR-free survival in patients with CH (P = 0.0174). PCa with UH was associated with higher BCR than PCa with CH among resection margin (RM)-negative cases (P < 0.0001). Further, increased PI-RADS v2.1 score did not correlate with larger TV in UH (P = 0.991), whereas a significant difference in TV was observed in CH (P < 0.0001). The prognostic significance of UH tumor was independent of tumor localization, and shorter BCR-free survival was observed even in RM-negative cases, indicating an aggressive subtype with micro-metastatic potential. Furthermore, UH tumors may decrease visibility on MRI. These findings will help optimal perioperative management for PCa with UH.

show abstract

Section: Discussionmentioning

confidence: 99%

Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy

Kurokawa,

Yamada,

Sakamoto

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Xu et al found that IDC-P was a risk factor for pathological lymph node metastasis in patients with cT2N0M0 stage who underwent RP 25 . Comprehensive genome analysis revealed a higher frequency of alterations in tumor suppressor genes (e.g., TP53 , RB1 ) for UH cancers, which may manifest as these clinical features 26 . Furthermore, PTEN deficiency was frequently observed in patients with IDC-P, at 70–90% 27 .…”

Section: Discussionmentioning

confidence: 99%

Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy

Kurokawa,

Yamada,

Sakamoto

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The prognostic significance of unconventional histology (UH) subtypes including intraductal carcinoma of the prostate (IDC-P), ductal adenocarcinoma, and cribriform pattern has been investigated for prostate cancer (PCa). However, little is known about magnetic resonance imaging (MRI) features and the oncological impact of tumor localization in localized PCa with UH. Clinical data of 211 patients with acinar adenocarcinoma (conventional histology [CH]) and 82 patients with UH who underwent robotic-assisted radical prostatectomy (RARP) were reviewed. Patients with UH are more likely to be older and have higher Gleason grade group, higher Prostate Imaging-Reporting and Data System (PI-RADS) v2.1 score, and larger tumor volume (TV) than those with CH. Multivariate analysis identified the presence of UH as an independent prognostic factor for progression-free survival (PFS) (hazard ration (HR) 2.41, 95% confidence interval (CI) 0.22–0.79, P = 0.0073). No significant difference in PFS was seen regarding tumor localization (transition zone [TZ] or peripheral zone [PZ]) in patients with UH (P = 0.8949), whereas PZ cancer showed shorter PFS in patients with CH (P = 0.0174). PCa with UH was associated with higher progression than PCa with CH among resection margin (RM)-negative cases (P < 0.0001). Further, increased PI-RADS v2.1 score did not correlate with larger TV in UH (P = 0.991), whereas a significant difference in TV was observed in CH (P < 0.0001). The prognostic significance of UH tumor was independent of tumor localization, and shorter PFS was observed even in RM-negative cases, indicating an aggressive subtype with micro-metastatic potential. Furthermore, UH tumors are more likely to harbor a large TV despite PI-RADS v2.1 score ≤ 3. These findings will help optimal perioperative management for PCa with UH.

show abstract

Genomic analysis of aggressive ductal adenocarcinoma of the prostate

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Genomic profile analysis using next‐generation sequencing can potentially elucidate the pathogenesis of rare cancers. Ductal adenocarcinoma, a rare subtype of prostate cancer, has an aggressive nature. This is the first study to analyze the genomic profile of ductal adenocarcinoma in an Asian population. Methods We identified 12 patients newly diagnosed with ductal adenocarcinoma of the prostate at two hospitals, and nine patients (75.0%) had the pure type. Genomic assessment was performed using either the PleSSision testing platform or FoundationOne CDx. Results At least one genomic alteration occurred in 11 patients (91.7%), and the most frequently mutated gene was tumor suppressor protein p53 (TP53), which was found in six cases (50.0%). Alterations characteristic of this cohort were found in four cases (33.3%) of retinoblastoma transcriptional corepressor 1 (RB1), which was only observed in the pure type. Compared to previous study results, the frequency of genetic alterations in the phosphoinositide 3‐kinase (PI3K) pathway (n = 3; 25.0%) and Wnt‐β‐catenin pathway (n = 5; 41.7%) was comparable, but no alterations in the DNA damage repair (DDR) pathway were observed. None of the patients presented high tumor mutation burden or microsatellite instability. Conclusions We found that the Asian cohort with ductal adenocarcinoma had actionable alterations, and a high frequency of alterations in TP53 and RB1 reflected the aggressive nature of the tumor. Genetic analysis using next‐generation sequencing is expected to help elucidate the pathogenesis of ductal adenocarcinoma.

show abstract

Genomic analysis of aggressive ductal adenocarcinoma of the prostate

Cited by 5 publications

References 38 publications

Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy

Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy

Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy

Genomic analysis of aggressive ductal adenocarcinoma of the prostate

Contact Info

Product

Resources

About